![Peder Sven Walberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peder Sven Walberg
Fondateur chez
Immedica Pharma AB
Fortune : 19 M $ au 31/05/2026
Profil
Peder Sven Walberg was the founder of Wilson Therapeutics AB, founded in 2012, where the title held was Director from 2012 to 2015.
Dr. Walberg was the founder of Rare Thyroid Therapeutics International AB, founded in 2017, where the title held was Chief Executive Officer & Director from 2017 to 2020.
Dr. Walberg is also the founder of Immedica Pharma AB..
Dr. Walberg is currently Chief Executive Officer & Director at Cetoros AB, Chairman & Chief Executive Officer at TTM HoldCo AB, Director at Immedica Pharma Holding AB, and Director at Akiram Therapeutics AB. Former positions include Director at OxThera AB from 2011 to 2016, Director at Egetis Therapeutics AB from 2021 to 2024, Head-Business Development & Licensing at Novartis AG from 2005 to 2007, Management & Strategy Consultant at The Boston Consulting Group, Inc., EVP-Business Development & Strategy at Swedish Orphan International Holding AB, and EVP-Business Development & Strategy at Swedish Orphan Biovitrum AB from 2010 to 2011.
Education includes undergraduate and doctorate degrees from the University of Uppsala and an undergraduate degree from the Swedish Armed Forces Language Institute.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EGETIS THERAPEUTICS AB 6,19 % | 31/05/2026 | 28 776 221 ( 6,19 % ) | 19 M $ | 31/05/2026 |
Postes actifs de Peder Sven Walberg
| Sociétés | Poste | Début |
|---|---|---|
Immedica Pharma AB
 Immedica Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops medicines for rare, genetic and metabolic diseases, hematology & oncology and specialty care | Fondateur | - |
Cetoros AB | Directeur Général | - |
Immedica Pharma Holding AB
 Immedica Pharma Holding AB MiscellaneousMiscellaneous Functions as an investment holding company | Directeur/Membre du Conseil | - |
TTM HoldCo AB | Directeur Général | - |
Anciens postes connus de Peder Sven Walberg
| Sociétés | Poste | Fin |
|---|---|---|
| EGETIS THERAPEUTICS AB | Directeur Technique/Scientifique/R&D | 01/05/2021 |
Rare Thyroid Therapeutics International AB
 Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Provides thyroid therapeutics research services | Fondateur | 01/11/2020 |
OxThera AB
 OxThera AB Medical/Nursing ServicesHealth Services Develops novel treatments for hyperoxaluria leading to kidney damage and potential organ failure | Directeur/Membre du Conseil | 01/01/2016 |
| WILSON THERAPEUTICS AB | Fondateur | 01/01/2015 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01/01/2011 |
Formation de Peder Sven Walberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
47
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Swedish Orphan International Holding AB
 Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Develops, manufactures and sells pharmaceutical products and drugs | Health Technology |
University of Uppsala
 University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OxThera AB
OxThera AB Medical/Nursing ServicesHealth Services Develops novel treatments for hyperoxaluria leading to kidney damage and potential organ failure | Health Services |
Swedish Armed Forces Language Institute
 Swedish Armed Forces Language Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Egetis Therapeutics AB
 Egetis Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Immedica Pharma AB
Immedica Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops medicines for rare, genetic and metabolic diseases, hematology & oncology and specialty care | Health Technology |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company focusing in treatment of Wilson disease | Health Technology |
Rare Thyroid Therapeutics International AB
Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Provides thyroid therapeutics research services | Health Technology |
Cetoros AB | |
Immedica Pharma Holding AB
Immedica Pharma Holding AB MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
TTM HoldCo AB |
